TARS
Tarsus Pharmaceuticals, Inc.$56.77+0.67 (+1.19%)Prev Close$56.11·MCap$2.55B·P/E—·Vol983.2K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
21
$16.30M
◆
Net Activity
Net Seller
$16.30M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Tarsus Pharmaceuticals, Inc. (TARS) has been exclusively selling, with 0 insider purchases totaling $0.00 and 21 insider sales totaling $16.30M. The most recent insider transaction was by Azamian Bobak R. (director, officer: President/CEO and Board Chair), who sold $615.5K worth of shares on Jun 22, 2026. Tarsus Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.55B.
TARS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Azamian Bobak R. | director, officer: President/CEO and Board Chair | Sell | 10,000 | $61.55 | $615.5K | 853,409 |
| Jun 17, 2026 | LINK WILLIAM J PHD | director | Sell | 12,500 | $62.12 | $776.5K | 108,714 |
| Jun 17, 2026 | Farrow Jeffrey S | officer: See Remarks | Sell | 14,396 | $60.95 | $877.4K | 56,801 |
| Jun 17, 2026 | Goodrich Katherine | director | Sell | 2,954 | $62.08 | $183.4K | 2,233-57% |
| Mar 24, 2026 | Neervannan Seshadri | officer: Chief Operating Officer | Sell | 2,989 | $66.75 | $199.5K | 82,791 |
| Mar 19, 2026 | Azamian Bobak R. | director, officer: President/CEO and Board Chair | Sell | 34,603 | $68.34 | $2.36M | 57,052-38% |
| Mar 19, 2026 | Farrow Jeffrey S | officer: See Remarks | Sell | 6,430 | $68.36 | $439.6K | 47,635 |
| Mar 19, 2026 | Lin Elizabeth Yeu | officer: Chief Medical Officer | Sell | 1,144 | $68.36 | $78.2K | 24,077 |
| Mar 19, 2026 | Mottiwala Aziz | officer: Chief Commercial Officer | Sell | 13,056 | $68.36 | $892.5K | 70,250 |
| Mar 19, 2026 | Neervannan Seshadri | officer: Chief Operating Officer | Sell | 11,324 | $68.21 | $772.4K | 93,979 |
| Mar 19, 2026 | Wahl Bryan | officer: General Counsel | Sell | 12,440 | $68.36 | $850.4K | 72,315 |
| Mar 19, 2026 | Whitfield Dianne C. | officer: Chief Human Resources Officer | Sell | 12,274 | $68.36 | $839.1K | 43,273 |
| Mar 18, 2026 | LINK WILLIAM J PHD | director | Sell | 12,500 | $68.79 | $859.8K | 125,203 |
| Jan 2, 2026 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 15,565 | $80.67 | $1.26M | 0 |
| Dec 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $82.51 | $495.1K | 0 |
| Dec 16, 2025 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 7,397 | $80.10 | $592.5K | 0 |
| Dec 15, 2025 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2,078 | $79.50 | $165.2K | 0 |
| Dec 15, 2025 | LINK WILLIAM J PHD | Director | Sell | 22,946 | $81.26 | $1.86M | 0 |
| Sep 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $55.37 | $332.2K | 0 |
| Sep 8, 2025 | LINK WILLIAM J PHD | Director | Sell | 27,116 | $57.00 | $1.55M | 0 |
| Aug 11, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $50.00 | $300.0K | 0 |
| Jun 16, 2025 | Farrow Jeffrey S | See Remarks | Sell | 13,608 | $40.42 | $550.0K | 0 |
| Jun 13, 2025 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 1,006 | $41.08 | $41.3K | 0 |
| Jun 9, 2025 | Mottiwala Aziz | Chief Commercial Officer | Sell | 17,500 | $43.76 | $765.8K | 0 |
| Mar 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $50.00 | $300.0K | 0 |
| Mar 18, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 24,216 | $48.03 | $1.16M | 0 |
| Mar 18, 2025 | Farrow Jeffrey S | See Remarks | Sell | 3,724 | $47.88 | $178.3K | 0 |
| Mar 18, 2025 | Mottiwala Aziz | Chief Commercial Officer | Sell | 10,565 | $47.88 | $505.9K | 0 |
| Mar 18, 2025 | Neervannan Seshadri | Chief Operating Officer | Sell | 7,583 | $47.89 | $363.1K | 0 |
| Mar 18, 2025 | Wahl Bryan | General Counsel | Sell | 9,686 | $47.88 | $463.8K | 0 |
| Mar 18, 2025 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 6,711 | $47.88 | $321.3K | 0 |
| Aug 14, 2024 | LINK WILLIAM J PHD | Sell | 35,000 | $26.08 | $913.0K | 5,021-87% | |
| Jun 20, 2024 | Farrow Jeffrey S | See Remarks | Sell | 10,445 | $27.47 | $286.9K | 18,136-37% |
| Mar 19, 2024 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 10,415 | $30.60 | $318.7K | 26,456-28% |
| Mar 19, 2024 | Mottiwala Aziz | Chief Commercial Officer | Sell | 4,766 | $30.60 | $145.8K | 54,075 |
| Mar 19, 2024 | Neervannan Seshadri | Chief Operating Officer | Sell | 4,879 | $30.60 | $149.3K | 64,767 |
| Mar 19, 2024 | Wahl Bryan | General Counsel | Sell | 4,436 | $30.60 | $135.7K | 40,951 |
| Mar 19, 2024 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 4,314 | $30.60 | $132.0K | 34,181 |
| Dec 29, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $20.22 | $161.8K | 830,106 |
| Dec 22, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 40,000 | $20.27 | $810.6K | 868,663 |
| Dec 22, 2023 | Trevejo Jose M. | CHIEF MEDICAL OFFICER | Sell | 2,252 | $20.00 | $45.0K | 2,251-50% |
| Dec 19, 2023 | Goldberg Andrew D. | Director | Buy | 1,000 | $18.96 | $19.0K | 3,000+50% |
| Dec 1, 2023 | Wahl Bryan | General Counsel | Sell | 8,356 | $16.31 | $136.3K | 31,966 |
| Dec 1, 2023 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 8,355 | $16.31 | $136.3K | 26,784 |
| Nov 17, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $18.37 | $146.9K | 883,210 |
| Oct 20, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $13.24 | $105.9K | 886,106 |
| Oct 6, 2023 | Trevejo Jose M. | CHIEF MEDICAL OFFICER | Sell | 1,604 | $18.00 | $28.9K | 4,503-26% |
| Sep 22, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $17.21 | $137.7K | 894,106 |
| Aug 25, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $17.23 | $137.8K | 902,106 |
| Aug 17, 2023 | Lin Elizabeth Yeu | Director | Buy | 9,506 | $16.80 | $159.7K | 15,866+149% |
Showing 1–50 of 144
1 / 3
TARS Insider Buying Activity
The following table shows recent insider purchases of Tarsus Pharmaceuticals, Inc. (TARS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | Goldberg Andrew D. | Director | Buy | 1,000 | $18.96 | $19.0K | 3,000+50% |
| Aug 17, 2023 | Lin Elizabeth Yeu | Director | Buy | 9,506 | $16.80 | $159.7K | 15,866+149% |
TARS Insider Selling Activity
The following table shows recent insider sales of Tarsus Pharmaceuticals, Inc. (TARS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Azamian Bobak R. | director, officer: President/CEO and Board Chair | Sell | 10,000 | $61.55 | $615.5K | 853,409 |
| Jun 17, 2026 | LINK WILLIAM J PHD | director | Sell | 12,500 | $62.12 | $776.5K | 108,714 |
| Jun 17, 2026 | Farrow Jeffrey S | officer: See Remarks | Sell | 14,396 | $60.95 | $877.4K | 56,801 |
| Jun 17, 2026 | Goodrich Katherine | director | Sell | 2,954 | $62.08 | $183.4K | 2,233-57% |
| Mar 24, 2026 | Neervannan Seshadri | officer: Chief Operating Officer | Sell | 2,989 | $66.75 | $199.5K | 82,791 |
| Mar 19, 2026 | Azamian Bobak R. | director, officer: President/CEO and Board Chair | Sell | 34,603 | $68.34 | $2.36M | 57,052-38% |
| Mar 19, 2026 | Farrow Jeffrey S | officer: See Remarks | Sell | 6,430 | $68.36 | $439.6K | 47,635 |
| Mar 19, 2026 | Lin Elizabeth Yeu | officer: Chief Medical Officer | Sell | 1,144 | $68.36 | $78.2K | 24,077 |
| Mar 19, 2026 | Mottiwala Aziz | officer: Chief Commercial Officer | Sell | 13,056 | $68.36 | $892.5K | 70,250 |
| Mar 19, 2026 | Neervannan Seshadri | officer: Chief Operating Officer | Sell | 11,324 | $68.21 | $772.4K | 93,979 |
| Mar 19, 2026 | Wahl Bryan | officer: General Counsel | Sell | 12,440 | $68.36 | $850.4K | 72,315 |
| Mar 19, 2026 | Whitfield Dianne C. | officer: Chief Human Resources Officer | Sell | 12,274 | $68.36 | $839.1K | 43,273 |
| Mar 18, 2026 | LINK WILLIAM J PHD | director | Sell | 12,500 | $68.79 | $859.8K | 125,203 |
| Jan 2, 2026 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 15,565 | $80.67 | $1.26M | 0 |
| Dec 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $82.51 | $495.1K | 0 |
| Dec 16, 2025 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 7,397 | $80.10 | $592.5K | 0 |
| Dec 15, 2025 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 2,078 | $79.50 | $165.2K | 0 |
| Dec 15, 2025 | LINK WILLIAM J PHD | Director | Sell | 22,946 | $81.26 | $1.86M | 0 |
| Sep 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $55.37 | $332.2K | 0 |
| Sep 8, 2025 | LINK WILLIAM J PHD | Director | Sell | 27,116 | $57.00 | $1.55M | 0 |
| Aug 11, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $50.00 | $300.0K | 0 |
| Jun 16, 2025 | Farrow Jeffrey S | See Remarks | Sell | 13,608 | $40.42 | $550.0K | 0 |
| Jun 13, 2025 | Lin Elizabeth Yeu | Chief Medical Officer | Sell | 1,006 | $41.08 | $41.3K | 0 |
| Jun 9, 2025 | Mottiwala Aziz | Chief Commercial Officer | Sell | 17,500 | $43.76 | $765.8K | 0 |
| Mar 24, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 6,000 | $50.00 | $300.0K | 0 |
| Mar 18, 2025 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 24,216 | $48.03 | $1.16M | 0 |
| Mar 18, 2025 | Farrow Jeffrey S | See Remarks | Sell | 3,724 | $47.88 | $178.3K | 0 |
| Mar 18, 2025 | Mottiwala Aziz | Chief Commercial Officer | Sell | 10,565 | $47.88 | $505.9K | 0 |
| Mar 18, 2025 | Neervannan Seshadri | Chief Operating Officer | Sell | 7,583 | $47.89 | $363.1K | 0 |
| Mar 18, 2025 | Wahl Bryan | General Counsel | Sell | 9,686 | $47.88 | $463.8K | 0 |
| Mar 18, 2025 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 6,711 | $47.88 | $321.3K | 0 |
| Aug 14, 2024 | LINK WILLIAM J PHD | Sell | 35,000 | $26.08 | $913.0K | 5,021-87% | |
| Jun 20, 2024 | Farrow Jeffrey S | See Remarks | Sell | 10,445 | $27.47 | $286.9K | 18,136-37% |
| Mar 19, 2024 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 10,415 | $30.60 | $318.7K | 26,456-28% |
| Mar 19, 2024 | Mottiwala Aziz | Chief Commercial Officer | Sell | 4,766 | $30.60 | $145.8K | 54,075 |
| Mar 19, 2024 | Neervannan Seshadri | Chief Operating Officer | Sell | 4,879 | $30.60 | $149.3K | 64,767 |
| Mar 19, 2024 | Wahl Bryan | General Counsel | Sell | 4,436 | $30.60 | $135.7K | 40,951 |
| Mar 19, 2024 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 4,314 | $30.60 | $132.0K | 34,181 |
| Dec 29, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $20.22 | $161.8K | 830,106 |
| Dec 22, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 40,000 | $20.27 | $810.6K | 868,663 |
| Dec 22, 2023 | Trevejo Jose M. | CHIEF MEDICAL OFFICER | Sell | 2,252 | $20.00 | $45.0K | 2,251-50% |
| Dec 1, 2023 | Wahl Bryan | General Counsel | Sell | 8,356 | $16.31 | $136.3K | 31,966 |
| Dec 1, 2023 | Whitfield Dianne C. | Chief Human Resources Officer | Sell | 8,355 | $16.31 | $136.3K | 26,784 |
| Nov 17, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $18.37 | $146.9K | 883,210 |
| Oct 20, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $13.24 | $105.9K | 886,106 |
| Oct 6, 2023 | Trevejo Jose M. | CHIEF MEDICAL OFFICER | Sell | 1,604 | $18.00 | $28.9K | 4,503-26% |
| Sep 22, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $17.21 | $137.7K | 894,106 |
| Aug 25, 2023 | Azamian Bobak R. | President/CEO and Board Chair | Sell | 8,000 | $17.23 | $137.8K | 902,106 |
TARS Insiders
Similar Stocks to TARS
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B